SEATTLE, July 18, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a
clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast
conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies
being conducted by Translational Drug Development, LLC (“TD2”). The purpose of the initial study is to develop and validate
preclinical methods of using Atossa’s proprietary intraductal microcatheter technology to administer immunotherapy to the site of
tumor initiation.
“While there has been recent success treating blood cancers with chimeric antigen receptor therapy (or, CAR-T), there has not
been much success using CAR-T to treat solid tumors like breast cancer,” commented Steve Quay, Ph.D., MD, President and CEO of
Atossa. “We are, however, encouraged by a recent case study reported June 4, 2018 in Nature Medicine (N. Zacharakis, et
al.), in which a patient with metastatic breast cancer who was not responding to chemotherapy had complete tumor regression 22
months after being treated with an intravenous infusion of eighty billion T-cells and interleukin. We believe our proprietary
intraductal microcatheter technology may provide a unique and more efficacious and cost-effective treatment method by delivering a
significantly smaller number of T-cells directly to the site of the cancer prior to metastasis, rather than through the blood
stream, where they are diluted into the entire body. These studies are the first of several steps to develop our intraductal
microcatheter technology to treat breast cancer with cell-based immunotherapy, such as CAR-T. These pre-clinical studies will form
the basis for the design of human studies, with the ultimate goal of treating breast cancer by administering an immunotherapy with
our proprietary microcatheter technology,” added Dr. Quay.
The studies are being conducted for Atossa by Translational Drug Development, LLC, which is an oncology development organization
that provides innovative services and is uniquely positioned to support improved and accelerated development of medicines for
life-threatening oncology diseases.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat
breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
About TD2
TD2 supports oncology-focused companies by providing a unique and translational set of services to accelerate drug
development. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 applies
thorough and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize
clinical trial design and execution. For more information, visit www.TD2inc.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the
FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary
rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under
development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 866 893-4927
kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott Gordon
CoreIR
377 Oak Street
Concourse 2
Garden City, NY 11530
Office: 516 222-2560
scottg@CoreIR.com
Source: Atossa Genetics Inc.
![Primary Logo](https://resource.globenewswire.com/Resource/Download/25b79114-0ca0-4348-a136-9afce33e910d?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzMyODg1Mg==)